Skip to Main Content

Paper Details

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
J Clin Oncol
83
2020
Children, DIN, Dinutuximab, GM-CSF, Irinotecan, Neuroblastoma, PATIENTS, Patients, Temozolomide, diarrhea, fever, granulocyte-macrophage colony-stimulating factor, hypoxia, irinotecan, neuroblastoma, neutropenia, patient, patients, relapsed/refractory, relapsed/refractory neuroblastoma, temozolomide
Author NameAffiliation
Rajen ModyC.S. Mott Children's Hospital, University of Michigan ann arbor
John M MarisChildren's Hospital of Philadelphia and University of Pennsylvania
John M MarisChildren's Hospital of Philadelphia and University of Pennsylvania
Rochelle BagatellChildren's Hospital of Philadelphia and University of Pennsylvania
  • 1 - 4

Datasets

Release 1.2